摘要
糖原合成酶激酶-3β(GSK-3β)是一种丝氨酸/苏氨酸蛋白激酶,大量的实验研究证明GSK-3β与缺血-再灌注损伤密切相关,缺血预处理、后处理及许多心肌保护药物被认为都是通过调节GSK-3β来发挥他们的心肌保护作用,而且GSK-3β被认为是一个心肌肥大的负调节因子。鉴于GSK-3β与心血管疾病的密切相关性。该文将GSK-3β在缺血-再灌注损伤及心肌肥大中的作用及其机制作一综述。
出处
《国际心血管病杂志》
2010年第1期24-26,共3页
International Journal of Cardiovascular Disease
参考文献18
-
1Liao R, Force T. Not all hypertrophy is created equal[J]. Cire Res, 2007, 101(11) : 1069 -1072.
-
2Doble BW, Woodgett JR. GSK 3: tricks of the trade for a multi tasking kinase[J].J Cell Sci, 2003, 116 (Pt 7): 1175-1186.
-
3Kerkela R, Woulfe K, Force T. Glycogen synthase kinase- 3beta-actively inhibiting hypertrophy [J]. Trends Cardiovasc Med, 2007, 17(3): 91- 96.
-
4Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative larger for cardioprotection [J]. Cell Physiol Biochem, 2007, 20(1-4) : 1-22.
-
5Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore [J].J Clin Invest, 2004, 113(11): 1535-1549.
-
6Das S, Wong R, Rajapakse N, et al. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation[J]. Cire Res, 2008, 103(9): 983- 991.
-
7Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death[J]. Cardiovasc Res, 2008, 77(2): 334-343.
-
8Juhaszova M, Wang S, Zorov DB, et al. The identity and regulation of the mitoehondrial permeability transition pore: where the known meets the unknown[J]. Ann N Y Aead Sci, 2008, 1123:197- 212.
-
9Zhai P, Sadoshima J. Overcoming an energy crisis?: an adap rive role of glycogen synthase kinase-3 inhibition in ischemial reperfusion[J]. CircRes, 2008, 103(9): 910 -913.
-
10Freeman RS, Barone MC. Targeting hypoxia-indueible factor (HIF) as a therapeutic strategy for CNS disorders[J]. Curr Drug Targets CNS Neurol Disord, 2(t05, 4( 1 ) : 85-92.
同被引文献12
-
1Srivastava G,Mehta JL. Currying the heart:curcumin and cardioprotection[J].Journal of Cardiovascular Pharmacology and therapeutics,2009,(01):22-27.
-
2Chanoit G,Lee S,Xi J. Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase3beta[J].American Journal of Physiology-Heart and Circulatory Physiology,2008,(03):H1227-H1233.
-
3Zhou H,Beevers CS,Huang S. The targets of curcumin[J].Current Drug Targets,2011,(03):332-347.
-
4Forde JE,Dale TC. Glycogen synthase kinase 3:a key regulator of cellular fate[J].Cellular and Molecular Life Sciences,2007,(15):1930-1944.doi:10.1007/s00018-007-7045-7.
-
5Jope RS,Johnson GV. The glamour and gloom of glycogen synthase kinase-3[J].Trends in Biochemical Sciences,2004,(02):95-102.doi:10.1016/j.tibs.2003.12.004.
-
6Vasileva AK,Plotnikov EY,Kazachenko AV. Inhibition of GSK-3β decreases the ischemiainduced death of renal cells[J].Bulletin of Experimental Biology and Medicine,2010,(03):303-307.
-
7Cuzzocrea S,Mazzon E,Esposito E. Glycogen synthase kinase-3beta inhibition attenuates the development of ischemia/reperfusion injury of the gut[J].Intensive Care Medicine,2007,(05):880-893.doi:10.1007/s00134-007-0595-1.
-
8Collino M,Thiemermann C,Mastrocola R. Treatment with the glycogen synthase kinase3beta inhibitor,TDZD-8,affects transient cerebral ischemia/reperfusion injury in the rat hippocampus[J].Shock,2008,(03):299-307.doi:10.1097/SHK.0b013e318164e762.
-
9Gao HK,Yin Z,Zhou N. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis[J].Journal of Cardiovascular Pharmacology and therapeutics,2008,(03):286-292.
-
10Zhai P,Sciarretta S,Galeotti J. Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion[J].Circulation Research,2011,(05):502-511.
二级引证文献9
-
1程阳,唐桥斐,赵丽妮.缺血再灌注诱导心肌细胞凋亡及凋亡相关基因表达的研究[J].中国卫生产业,2014,11(17):141-142.
-
2孙佳琳,庞磊,王帅,孟宪生,包永睿.基于微流控芯片技术建立缺血再灌注心肌损伤模型[J].中国药科大学学报,2014,45(6):710-714. 被引量:4
-
3杨述亮,韩燕,李占清.PI3K/AKT/GSK-3β信号通路与心肌缺血/再灌注损伤的相关性研究[J].医学综述,2015,21(9):1571-1574. 被引量:20
-
4李明芬.姜黄素对缺血再灌注损伤器官的保护作用[J].海峡药学,2016,28(2):139-141. 被引量:1
-
5廖小香.姜黄素对心房颤动大鼠心房肌细胞Kir2.1,KvLQT1,HERG基因表达的影响[J].中国药业,2016,25(13):8-10.
-
6陈文军,陈素枝,靳晓华,檀金川.降脂通络软胶囊对膜性肾病大鼠肾保护作用及对肾组织Bcl-2和Bad表达的影响[J].中草药,2016,47(18):3263-3268. 被引量:14
-
7朱盼盼,徐彤彤,彭丽,武琦,王文艳,赵位昆.姜黄素减轻心肌缺血再灌注损伤的研究进展[J].广西医学,2021,43(6):750-753. 被引量:1
-
8李成,许静,孙晓旻,杨欢,姚景春,陈绪龙.基于反向分子对接和网络药理学探讨姜黄素抗肿瘤作用机制[J].江西中医药,2022,53(10):59-67.
-
9苏琦,赵娜,苗雨欣,李朝阳,肖童,孙雅涵,何玛丽,田炜,徐菁蔓.银杏内酯B抗心肌氧化应激损伤作用机制研究[J].中国中医基础医学杂志,2019,25(7):918-921. 被引量:1
-
1崔毅,郑惠民,金军,谢惠君,丁素菊,刘莹.遗传性运动感觉神经病合并心肌肥大的研究[J].中华神经科杂志,1996,29(3):155-155. 被引量:1
-
2张洪,许旌,杨帆,刘莹露.补肾健脾方对阿尔茨海默病模型大鼠胰岛素和GSK-3β水平的影响[J].山东中医药大学学报,2011,35(1):73-74. 被引量:4
-
3王亚,喇孝瑾,邱昌龙,高秀娟,曹福源,田炜,李继安.五子降糖方对2型糖尿病模型大鼠肝组织糖原及AKT/GSK-3β信号通路的影响[J].北京中医药大学学报,2014,37(2):107-111. 被引量:5
-
4张志慧,吴相春,葛小丽,周龙岗,魏聪.信号通路糖原合成酶激酶-3β在β淀粉样蛋白损伤脑微血管内皮细胞Tau蛋白表达中的作用及通心络干预研究[J].中国实验方剂学杂志,2010,16(10):116-118. 被引量:2
-
5许旌,张洪,苏爱梅,包三裕.小檗碱脂质体对代谢综合征患者大网膜脂肪组织GSK-3β磷酸化的调节作用[J].山东中医药大学学报,2014,38(4):389-391.
-
6赖日明,朱原,郑丽娴,张继平.补阳还五汤对脑缺血再灌注损伤大鼠GSK3β mRNA的影响[J].广州中医药大学学报,2016,33(3):362-366. 被引量:5
-
7陈北阳,李花,熊艾君.三七总皂苷对脑缺血再灌注后海马CA1区损伤的影响[J].湖南中医学院学报,2004,24(4):4-6. 被引量:8
-
8赵唯贤,李宜培,李高申,刘建涛,王保伟,郭梅珍.逍遥散对大鼠阿尔茨海默病模型海马CA1区相关指标的影响[J].中国中医基础医学杂志,2014,20(7):898-900. 被引量:1
-
9王晓丽,孙影,朱兰芹,綦艳秋,张丽华,张红宇,董妙先.镇肝熄风汤对帕金森病肝阳上亢证大鼠中脑Akt和GSK-3β磷酸化的影响[J].世界科学技术-中医药现代化,2016,18(8):1374-1378. 被引量:10
-
10卫景沛,梁宪红,林金嬉,王拥军.灯盏细辛对大鼠缺血-再灌注损伤的保护作用[J].中国医药导报,2009,6(25):22-24. 被引量:4